Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value
UPPSALA, SE / / June 10, 2025 /
Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has signed three new work orders within its Pharma Services business, with a combined value of approximately SEK 2.5 million. The agreements are for TKa testing services with existing customers.
Two of the three work orders were placed by the Tier-1 (revenues >10 BUSD) U.S. pharmaceutical company which recently entered into a broader service agreement with Biovica, including a record-breaking SEK 4 million work order. These latest orders will support the development of next-generation CDK4/6 inhibitors. The orders are a combination of retrospective analysis, that will be performed in the coming months, and prospective analysis that will be performed over ~2 years.
"I'm pleased to see that our Pharma customers recognize the value of DiviTum® TKa and are returning for continued use. The reliable and meaningful data it provides continues to drive demand from leading pharmaceutical companies, who use it in the development of new cancer therapies that will benefit patients.," said Anders Rylander, CEO of Biovica.
Contact
Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: anders.rylander@biovica.com
Anders Morén, CFOPhone: +46 73 125 92 46E-mail: anders.moren@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com
Attachments
Biovica secures three new work orders in Pharma Services of 2,5 MSEK in value
SOURCE: Biovica International
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $42.94, denoting a +2.02% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Shares of the company have appreciated by 11.97% over the course of the past month, outperforming the Medical sector's gain of 3.49% and the S&P 500's gain of 6.29%. Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.54 per share, which would represent a year-over-year decline of 3.36%. At the same time, our most recent consensus estimate is projecting a revenue of $5.89 million, reflecting a 1032.88% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.54 per share and revenue of $39.95 million, indicating changes of -27.65% and +7.06%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 1.68% fall in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 76, placing it within the top 31% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Geek Vibes Nation
an hour ago
- Geek Vibes Nation
How ChatGPT Bots Handle Client DMs While I Sleep – And Land Me New Deals
A good fit Ready to start Needing more info' This prompt works with DM automation tools that support branching logic. I collect info while I sleep – and wake up knowing which leads are warm. Claude Prompt #6 – Turn Chat Transcripts Into CRM Notes Prompt: 'Summarize this DM chat into 3 bullet points for my CRM: Who they are What they need How to follow up' This is huge when you're juggling 20 conversations. Claude acts like a personal assistant that cleans up your notes, flags key info, and saves it to Notion, Airtable, or whatever you use. AI DM Bot Comparison Use Case Best Model Why It Works Warm intro DM ChatGPT Fast, friendly, low-friction copy Deep context follow-up Claude Reads nuance and builds trust FAQ automation ChatGPT Clear, reusable, scalable replies Lead qualification Claude Detects readiness, helps filter CRM note generation Claude Great for summarizing long convos The Real Win – Focus on Closing, Not Replying Since I implemented this ChatGPT + Claude + Chatronix setup, I spend less time chasing leads and more time closing deals. I don't lose prospects because I replied too late. I don't drop the ball on follow-ups. And I don't miss qualified leads buried in my DMs. It's not about automating relationships – it's about automating friction so real connection can happen. Want your DMs to work while you rest? ✅ Visit Chatronix and set up your dream AI sales assistant – without hiring anyone. Emily Henry writes for UKWritings Reviews and Write My Research Paper . She writes articles on many subjects including writing great resumes. Emily is also an editor at State Of Writing .
Yahoo
an hour ago
- Yahoo
Women issued safety warning over period tracker apps
Experts have warned that women using period tracker apps face "real and frightening privacy and safety risks." Academics from the University of Cambridge have said that personal information within the app can be collected and "sold at scale." A new report from the Minderoo Centre for Technology and Democracy at Cambridge stated that this poses risks and harms for users. Researchers have said that menstrual data can provide insights into people's health and their reproductive choices. The apps can collect information on exercise, diet, medication, sexual preferences, hormone levels, and contraception use. The authors of the report added that this information can be a "gold mine" for consumer profiling. Many women who download the apps do so when they are trying to get pregnant, which the authors point out leads to a dramatic shift in shopping behaviour. 'Data on who is pregnant, and who wants to be, has therefore emerged as some of the most sought-after information in digital advertising,' they said. The point out how period tracking apps have rapidly risen in popularity, with global downloads of the three most popular apps surpassing 250 million. 'Cycle tracking apps (CTA) are a lucrative business because they provide the companies behind the apps with access to extremely valuable and fine-grained user data,' the experts wrote in their new report. 'CTA data is not only commercially valuable and shared with an inextricable net if third parties (thereby making intimate user information exploitable for targeted advertising), but it also poses severe security risks for users.' They point out that in the wrong hands, the data collected by the apps could result in health insurance 'discrimination'; risks to job prospects or even domestic abuse. The research team called for better governance of the 'femtech' industry, including improved data security of these apps and for them to introduce 'meaningful consent options'. They also called for public health bodies to launch alternatives to commercial tracking apps. 'Menstrual cycle tracking apps are presented as empowering women and addressing the gender health gap,' said Dr Stefanie Felsberger, lead author of the report. 'Yet the business model behind their services rests on commercial use, selling user data and insights to third parties for profit.' 'There are real and frightening privacy and safety risks to women as a result of the commodification of the data collected by cycle tracking app companies.' Professor Gina Neff, executive director of Cambridge's Minderoo Centre, added: 'The use of cycle tracking apps is at an all-time high. 'Women deserve better than to have their menstrual tracking data treated as consumer data, but there is a different possible future.'
